Proteostasis Therapeutics, Inc. Announces Scientific Presentations at 13th Annual European Cystic Fibrosis Society Basic Scie...
March 28 2016 - 7:30AM
Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical
company developing small molecule therapeutics to treat diseases
caused by dysfunctional protein processing, such as cystic fibrosis
(CF), today announced two abstracts will be presented during the
flash poster presentation sessions at the 13th Annual European
Cystic Fibrosis Society Basic Science Conference. The meeting will
take place March 30-April 2 at Green Park Resort near Pisa, Italy.
The company will hold a conference call and webcast on March 30,
2016 at 4:00 p.m. ET to discuss the data being presented at the
conference and the company’s outlook for 2016.
Following is a schedule of the company’s flash poster
presentations and conference call:
Flash Presentations
Thursday, March
31Time: 2:30-3:30 p.m. CEST
Title: Characterization of CFTR amplifiers,
mutation-agnostic modulators that increase protein levels and
complement other CF therapeutic modalities
Friday, April
1Time: 6:30-7:30 p.m. CEST
Title: A novel corrector for F508del-CFTR
that complements existing CFTR modulators in vitro
Conference Call and Webcast
Wednesday, March
30Time: 4:00 p.m. ET
The conference call can be accessed by dialing 1-877-626-4740
(toll-free domestic) or 1-281-973-6278 (international) and
referring to conference ID 78792593. A live webcast and
accompanying slide presentation will be available on the Event
Calendar page in the Investors & Media section of the company’s
website, www.proteostasis.com. A replay of the webcast will be
available on the company’s website shortly after the conclusion of
the conference call.
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a biopharmaceutical company
dedicated to the discovery of groundbreaking therapies to treat
diseases caused by dysfunctional protein processing, such as cystic
fibrosis (CF). Headquartered in Cambridge, MA, the Proteostasis
Therapeutics team focuses on identifying therapies that modulate
the proteostasis imbalance in cells and restore protein function.
Proteostasis Therapeutics is currently enrolling eligible adults
with CF to participate in its Phase 1 clinical trials of PTI-428, a
unique CFTR modulator, called a CFTR amplifier, that when used in
combination with existing treatments and therapies has shown a
consistent positive effect on CFTR protein activity in pre-clinical
studies. In addition to its multiple programs in cystic fibrosis,
Proteostasis Therapeutics has formed collaborations with Biogen to
research and identify therapeutic candidates for neurodegenerative
disease and with Astellas Pharma, Inc. to research and identify
therapies targeting the Unfolded Protein Response (UPR) pathway.
For more information visit www.proteostasis.com.
Media Contact: Dan Budwick, Pure
Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com
Investor Contact:Luke Heagle, Pure
Communications, Inc.(910)
726-1372luke@purecommunicationsinc.com
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Apr 2024 to May 2024
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From May 2023 to May 2024